Published in Hum Mutat on January 01, 2001
BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res (2001) 1.66
BRCA2 mutations in 154 finnish male breast cancer patients. Neoplasia (2004) 0.88
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered Cancer Clin Pract (2016) 0.83
Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients. Breast Dis (2011) 0.80
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet (2007) 0.79
Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland. Fam Cancer (2010) 0.77
Hereditary breast and ovarian cancer. Hered Cancer Clin Pract (2008) 0.77
Practical Aspects of microRNA Target Prediction. Curr Mol Med (2011) 2.64
CUG repeats present in myotonin kinase RNA form metastable "slippery" hairpins. J Biol Chem (1997) 2.17
The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 2.01
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat (2007) 1.44
Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat (2005) 1.41
Patterns of cleavages induced by lead ions in defined RNA secondary structure motifs. J Mol Biol (1998) 1.38
Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci (1995) 1.36
Acute phase proteins as disease markers. Dis Markers (1987) 1.35
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat (2014) 1.35
BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat (2006) 1.33
Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clin Genet (2006) 1.29
IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol (2001) 1.28
Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene (1999) 1.24
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24
A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet (2005) 1.22
Heterogeneous nature of the acute phase response. Differential regulation of human serum amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells. J Immunol (1988) 1.16
Monokines regulate glycosylation of acute-phase proteins. J Exp Med (1987) 1.15
High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum Mutat (2000) 1.10
Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther (2007) 1.09
Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol (1981) 1.08
Analysis of magnesium, europium and lead binding sites in methionine initiator and elongator tRNAs by specific metal-ion-induced cleavages. Eur J Biochem (1989) 1.01
Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States. J Med Genet (2002) 1.00
Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland. Oncogene (1997) 1.00
Identification of the magnesium, europium and lead binding sites in E. coli and lupine tRNAPhe by specific metal ion-induced cleavages. FEBS Lett (1989) 0.99
Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer (2000) 0.98
Microheterogeneity of alpha 1-acid glycoprotein in the detection of intercurrent infection in systemic lupus erythematosus. Arthritis Rheum (1987) 0.98
Microheterogeneity forms of alpha 1-acid glycoprotein as indicators of rheumatoid arthritis activity. Clin Chim Acta (1987) 0.98
Prevalence of BRCA1 founder mutations in western Poland. Hum Mutat (2001) 0.97
Determination of lectin-sugar dissociation constants by agarose affinity electrophoresis. Anal Biochem (1986) 0.96
Soluble interleukin 6 receptor is biologically active in vivo. Cytokine (1995) 0.96
Combined SSCP/duplex analysis by capillary electrophoresis for more efficient mutation detection. Nucleic Acids Res (2001) 0.94
Direct quantitation of skin elasticity in systemic sclerosis. J Rheumatol (1990) 0.89
Microheterogeneity of alpha 1-acid glycoprotein in the detection of intercurrent infection in patients with rheumatoid arthritis. Arthritis Rheum (1989) 0.88
Interleukin-6-type cytokine-induced changes in acute phase protein glycosylation. Ann N Y Acad Sci (1995) 0.88
Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells. J Immunol (1996) 0.88
The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells. Oncogene (2001) 0.87
Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gene Ther (2010) 0.87
Hot nodules in children and adolescents in western Poland from 1996 to 2000: clinical analysis of 31 patients. J Pediatr Endocrinol Metab (2002) 0.86
Faster and cheaper PCR on a standard thermocycler. Acta Biochim Pol (1995) 0.85
Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood (1994) 0.85
Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) (2004) 0.84
Comparison of three immunoassays for C-reactive protein determination. Arch Immunol Ther Exp (Warsz) (1985) 0.84
Specific RNA cleavages induced by manganese ions. FEBS Lett (1995) 0.82
Survival from breast cancer in patients with CHEK2 mutations. Breast Cancer Res Treat (2014) 0.82
Effect of modified nucleotides on structure of yeast tRNA(Phe). Comparative studies by metal ion-induced hydrolysis and nuclease mapping. Biochimie (1996) 0.82
New protein and PCR markers RAK for diagnosis, prognosis and surgery guidance for breast cancer. Cancer Lett (1997) 0.82
The in vitro production of alpha--fetoprotein variants by human fetal organs. Oncodev Biol Med (1980) 0.82
Diagnostic evaluation of cancer antigens RAK .1. Cervical and ovarian cancer. Int J Oncol (1996) 0.82
Helicobacter pylori from duodenal ulcer patients expresses inducible nitric oxide synthase immunoreactivity in vivo and in vitro. J Physiol Pharmacol (1996) 0.82
The reaction of adenine and cytosine residues in tRNA with chloroacetaldehyde. Nucleic Acids Res (1981) 0.81
Chemical modification of N6-(N-threonylcarbonyl) adenosine. Part II. Condensation of the carboxyl group with amines. Nucleic Acids Res (1979) 0.81
Development of a double-copy bicistronic retroviral vector for human gene therapy. Adv Exp Med Biol (1998) 0.81
Thyroid metastases from a breast cancer diagnosed by fine-needle aspiration biopsy. Case report and overview of the literature. Exp Oncol (2012) 0.81
Gene-modified cellular vaccines: technologic aspects and clinical problems. Transplant Proc (2010) 0.80
Structural analysis of two plant 5S rRNA species and fragments thereof by lead-induced hydrolysis. Biochem Mol Biol Int (1996) 0.80
Minor microheterogeneity of alpha 1-acid glycoprotein in rheumatoid arthritis. Prog Clin Biol Res (1989) 0.79
Induction of C-reactive protein by cytokines in human hepatoma cell lines is potentiated by caffeine. Biochem J (1990) 0.79
Double-copy bicistronic retroviral vector platform for gene therapy and tissue engineering: application to melanoma vaccine development. Gene Ther (1997) 0.79
Novel BRCA2 mutation in a Polish family with hamartoma and two male breast cancers. J Med Genet (2002) 0.79
The importance of ceruloplasmin oxidase activity in patients with chronic lower limb atherosclerotic ischemia. Int Angiol (2007) 0.79
Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in alpha3-fucosylation of alpha1-acid glycoprotein. Glycoconj J (1998) 0.79
Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther (2004) 0.79
Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther (2000) 0.78
Interleukin-6-type cytokines affect glycosylation of acute phase proteins in vitro. Ann N Y Acad Sci (1995) 0.78
Allelic imbalance of BRCA1 transcript in the IVS20 12-bp insertion carrier. Hum Mutat (2000) 0.78
C-reactive protein and alpha 1-acid glycoprotein in monitoring of patients with acute arterial occlusion. Eur J Vasc Surg (1991) 0.78
Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin Biol Ther (2001) 0.78
Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia (2001) 0.77
Studies on microheterogeneity of acute-phase proteins in rheumatoid arthritis by using crossed affinoimmuno-electrophoresis with free concanavalin A. Behring Inst Mitt (1986) 0.77
Affinity electrophoresis for diagnosis of cancer and inflammatory conditions. Electrophoresis (1989) 0.77
IL-11 is a potent anti-melanoma factor. Adv Exp Med Biol (2001) 0.77
Clinical characteristics of breast cancer in patients with an NBS1 mutation. Breast Cancer Res Treat (2013) 0.77
Hypermodified nucleoside carboxyl group as a target site for specific tRNA modification. Eur J Biochem (1986) 0.77
Specificity and mechanism of the cleavages induced in yeast tRNAPhe by magnesium ions. Acta Biochim Pol (1989) 0.77
C-reactive protein and alpha-1-acid glycoprotein in monitoring of patients with chronic arterial occlusion of the lower limbs. Eur J Vasc Surg (1993) 0.77
Genetically modified tumour vaccines--where we are today. Cancer Treat Rev (1999) 0.76
Lectin staining of renal tubules in normal kidney. APMIS (1997) 0.76
Genetically modified dendritic cells--a new, promising cancer treatment strategy? Expert Opin Biol Ther (2002) 0.76
Recent developments in retroviral gene delivery systems. Expert Opin Biol Ther (2001) 0.76
[Morphological features of colostrum and human milk cells]. Pol Tyg Lek (1971) 0.76
Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett (2000) 0.76
The reactions of thiouridines and thiouracils with chloroacetaldehyde; mechanistic considerations. Nucleic Acids Res (1980) 0.75
Long-range conformational transition in yeast tRNAPhe, induced by the Y-base removal and detected by chloroacetaldehyde modification. Nucleic Acids Res (1983) 0.75
[Acute phase proteins in systemic lupus erythematosus]. Pol Arch Med Wewn (1987) 0.75
[Structure of yeast tRNAPhe molecule]. Postepy Biochem (1984) 0.75
Chemical modification of adenine and cytosine residues with chloroacetaldehyde at the nucleoside and the tRNA level: the structural effect of chloroacetaldehyde modification. IARC Sci Publ (1986) 0.75